KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist clinical trials

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

This study is testing a new cancer medicine, TransCon TLR7/8 Agonist, sometimes given with another drug called Keytruda. It's for adults with advanced cancer. Researchers want to see if it's safe, what dose works best, and if it can shrink tumours.